Biocon Biologics, a subsidiary of Biocon, announced on Monday that it has secured multiple market access agreements in the US for its biosimilar Yesintek, a product highly similar to Stelara.
Yesintek, which was approved by the US FDA in December 2024, has demonstrated comparable pharmacokinetics, safety, efficacy, and immunogenicity to its reference product, according to clinical trials. The biosimilar is approved for treating Crohn&rsquo;s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis&mdash;common chronic autoimmune conditions.
US pharmacy benefit management firm Express Scripts has added Yesintek to its National Preferred Formulary (NPF) effective March 21. In parallel, US healthcare major Cigna has included the product in its commercial formulary starting the same date. Additionally, Blue Cross Blue Shield of Michigan, Florida Healthcare Plan, and several closed-door health systems have selected Yesintek as their exclusive ustekinumab product.
Yesintek is available in the same formulations as Stelara, including:
● 45 mg/0.5 mL prefilled syringe
● 90 mg/mL prefilled syringe
● 45 mg/0.5 mL vial
● 130 mg/26 mL vial
&nbsp;
Biocon Biologics is also finalising formulary agreements with additional commercial carriers.
&ldquo;Yesintek represents an important milestone for Biocon Biologics, as this is the first product we have launched in the United States as a fully integrated biosimilars company,&rdquo; said Shreehas Tambe, CEO &amp; Managing Director, Biocon Biologics. &ldquo;The listing of Yesintek on multiple formularies is another validation that payors in the US are committed to broadening access to affordable treatment options.&rdquo;
Josh Salsi, Head of North America at Biocon Biologics, noted that over 100 million Americans&mdash;representing 70 to 80% of the commercial market&mdash;are now covered for Yesintek through commercial formularies.
&nbsp;
Source : Business-standard

Biocon Biologics, a subsidiary of Biocon, announced on Monday that it has secured multiple market access agreements in the US for its biosimilar Yesintek, a product highly similar to Stelara.

Biocon Biologics Secures Multiple US Market Access Deals for Biosimilar Yesintek